ArticleClinical research in cardiology : official journal of the German Cardiac Society2020
Myeloperoxidase in atrial fibrillation: association with progression, origin and influence of renin-angiotensin system antagonists.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- The pcMPO-AF rule for predicting postoperative atrial fibrillation after coronary artery bypass grafting.Scientific reports · 2026Article
- Characteristics related to biomarkers of neutrophil, eosinophil, and mast cell activation.Scientific reports · 2025Article
- Pericardial Fluid Biomarkers as Early Predictors for Postoperative Atrial Fibrillation-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Role of NLRP3 Inflammasome in Heart Failure Patients Undergoing Cardiac Surgery as a Potential Determinant of Postoperative Atrial Fibrillation and Remodeling: Is SGLT2 Cotransporter Inhibition an Alternative for Cardioprotection?Antioxidants (Basel, Switzerland) · 2024Review
- Review
- Plasma myeloperoxidase: association with atrial fibrillation progression and recurrence after catheter ablation.Frontiers in cardiovascular medicine · 2023Article
- Causal relationship between levels of myeloperoxidase and obstructive sleep apnea: a bidirectional two-sample Mendelian randomization study.Frontiers in neurology · 2023Article
- The Role of Major Inflammatory Biomarkers in the Pathogenesis of Atrial Fibrillation.The Journal of innovations in cardiac rhythm management · 2022Article
- Immune remodeling and atrial fibrillation.Frontiers in physiology · 2022Review
- Markers of Inflammation, Oxidative Stress, and Fibrosis in Patients with Atrial Fibrillation.Oxidative medicine and cellular longevity · 2022Article
- Anti-inflammatory HDL effects are impaired in atrial fibrillation.Heart and vessels · 2022Article
- Article
- Electroimmunology and cardiac arrhythmia.Nature reviews. Cardiology · 2021Review
- SNP rs2243828 in MPO associated with myeloperoxidase level and atrial fibrillation risk in Chinese Han population.Journal of cellular and molecular medicine · 2020Article
- Pulmonary vein isolation treats symptomatic AF in a patient with Lamin A/C mutation: case report and review of the literature.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Review
- Inflammasomes and Proteostasis Novel Molecular Mechanisms Associated With Atrial Fibrillation.Circulation research · 2020Review
- Atrial fibrillation.Nature reviews. Disease primers · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloperoxidase (MPO), secreted by neutrophils under inflammatory conditions, is elevated in atrial fibrillation (AF). MPO may be involved in atrial remodeling that underpins AF progression characterized by a switch from paroxysmal to persistent AF and the formation of low-voltage areas (LVA). MPO levels are modulated by renin-angiotensin system antagonists (RAS-A), commonly used to treat AF comorbidities, and are associated with reduced AF incidence, implicating a potential link.
objectiveWe investigated MPO levels in progressing AF in peripheral and left atrial (LA) blood and analyzed a potential effect of RAS-A.
methodsSamples of AF patients were collected from the femoral vein and the LA during catheter ablation (n = 121) and at follow-up (n = 23). No-AF probands (n = 37) served as controls. MPO was determined using commercial ELISA.
resultsMPO levels were significantly increased in AF patients compared to controls (median, 27.7 ng/ml (IQR 14.3-66.6) versus 12.6 (IQR 9.9-17.7), p < 0.001), without differences between clinical AF progression phenotypes. MPO concentration was tenfold higher in LA than periphery (279.2 ng/ml (IQR 202.2-342.9) versus 27.7 ng/ml (IQR 14.3-65.9), p < 0.001). MPO remained increased at midterm follow-up irrespective of rhythm outcome. RAS-A was associated with significantly lower peripheral (22.2 ng/ml (IQR 12.7-48.2) versus 37.1 ng/ml (IQR 18.2-85.2), p < 0.05) MPO levels in AF patients.
conclusionThe pro-fibrotic enzyme MPO is generally elevated in AF patients irrespective of AF type, the presence of LVA or midterm rhythm outcome. Our data suggest that MPO may directly originate from the LA. RAS-A decrease peripheral MPO levels in AF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.